drugset / Trial / NCT05444088
Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the tolerability and safety of SHR-8068 in combination with Adebrelimab and Bevacizumab in subjects with advanced HCC; To evaluate the efficacy of SHR-8068 in combination with Adebrelimab and Bevacizumab in subjects with advanced HCC.
Timeline
- Start
- 2022-08-02
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SHR-8068 | Monoclonal antibody | — | Intravenous |
| Background | Adebrelimab | Monoclonal antibody | — | Intravenous |
| Background | Bevacizumab | Monoclonal antibody | — | Intravenous |